RxDoctor Payments Data

Joshua Pitre, MD

Dermatology · Baton Rouge, LANPI 1528421872

Payments from drug & device makers

$4,285in general payments, 2019–2025

Across 174 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Galderma Laboratories, L.p.$708
  • Lilly USA, LLC$583
  • Johnson & Johnson$351
  • Sanofi$266
  • Regeneron Healthcare Solutions, Inc.$217
  • plus $821 from 14 others

What the payments were for

  • Food & beverage$4,17397%
  • Education$1123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,285 in reported general payments places this provider in the 40th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$207,494
Medicare patients
549
Services billed
3,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab61$231,321
OtezlaApremilast16$80,303
Humira(Cf) PenAdalimumab11$74,163
Clobetasol Propionate219$7,847
Ketoconazole267$4,855
Betamethasone Valerate146$3,756
Tacrolimus25$3,492
Betamethasone Dipropionate67$3,400
Triamcinolone Acetonide243$3,002
Tretinoin40$2,548
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc162$2,448
Doxycycline Monohydrate171$2,139
Clindamycin Phosphate69$2,004
Mometasone Furoate87$1,559
Fluocinonide33$1,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$61$80,30316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →